Business Description
Century Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US15673T1007
Total Employee Number:
78Description
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.81 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.5 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 141.1 | |||||
3-Year EPS without NRI Growth Rate | 69.1 | |||||
3-Year FCF Growth Rate | -61.5 | |||||
3-Year Book Growth Rate | -29.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -47.75 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.56 | |||||
9-Day RSI | 48 | |||||
14-Day RSI | 50.08 | |||||
3-1 Month Momentum % | -5.75 | |||||
6-1 Month Momentum % | 63.85 | |||||
12-1 Month Momentum % | 287.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.25 | |||||
Quick Ratio | 10.25 | |||||
Cash Ratio | 9.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.4 | |||||
Shareholder Yield % | -27.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -87.46 | |||||
OCF Margin % | -86.58 | |||||
ROE % | -51.31 | |||||
ROA % | -38.62 | |||||
ROIC % | -76.89 | |||||
3-Year ROIIC % | -157.45 | |||||
ROC (Joel Greenblatt) % | -143.65 | |||||
ROCE % | -41.36 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 9 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.84 | |||||
PB Ratio | 1.57 | |||||
Price-to-Tangible-Book | 1.81 | |||||
EV-to-EBIT | -3.04 | |||||
EV-to-EBITDA | -3.45 | |||||
EV-to-Revenue | 3.02 | |||||
EV-to-Forward-Revenue | 6.83 | |||||
EV-to-FCF | -3.45 | |||||
Price-to-GF-Value | 0.06 | |||||
| Price-to-Net-Current-Asset-Value | 5.38 | |||||
| Price-to-Net-Cash | 5.65 | |||||
Earnings Yield (Greenblatt) % | -32.89 | |||||
FCF Yield % | -22.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IPSC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Century Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 109.164 | ||
| EPS (TTM) ($) | -1.14 | ||
| Beta | 2.4506 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.84 | ||
| Volatility % | 117.68 | ||
| 14-Day RSI | 50.08 | ||
| 14-Day ATR ($) | 0.178769 | ||
| 20-Day SMA ($) | 2.29875 | ||
| 12-1 Month Momentum % | 287.2 | ||
| 52-Week Range ($) | 0.435 - 3.04 | ||
| Shares Outstanding (Mil) | 180.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Century Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Century Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 37 days | ||
| General meeting for 2026 | 2026-06-11 09:00 | 2.12 (-3.64%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 2.29 (+0.00%) | ||
| Annual report for 2025 | 2026-03-12 | 2.73 (-2.15%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 2.73 (-2.15%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 16:20 | 2.94 (+14.84%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 09:50 | 2.28 (+4.59%) | ||
| 37th Annual Healthcare Conference | 2025-12-03 10:00 | 0.53 (-2.30%) | ||
| State of the Art in Cell Therapy” panel discussion | 2025-12-02 12:00 | 0.54 (-0.04%) |
Show
Entries
Century Therapeutics Inc Frequently Asked Questions
What is Century Therapeutics Inc(IPSC)'s stock price today?
The current price of IPSC is $2.32. The 52 week high of IPSC is $3.04 and 52 week low is $0.44.
When is next earnings date of Century Therapeutics Inc(IPSC)?
The next earnings date of Century Therapeutics Inc(IPSC) is 2026-08-14 Est..
Does Century Therapeutics Inc(IPSC) pay dividends? If so, how much?
Century Therapeutics Inc(IPSC) does not pay dividend.
Guru Commentaries on NAS:IPSC
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Century Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers